|
rs1799963
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Our findings suggest that the risk of VTE by FHMI is not explained by rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2066865 (FGG), and rs2036914 (F11).
|
31124268 |
2019 |
|
rs1799963
|
|
A |
0.730 |
GeneticVariation |
GWASCAT |
Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.
|
31676865 |
2019 |
|
rs1799963
|
|
|
0.730 |
GeneticVariation |
GWASCAT |
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.
|
31420334 |
2019 |
|
rs1799963
|
|
A |
0.730 |
GeneticVariation |
GWASCAT |
Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.
|
28373160 |
2017 |
|
rs1799963
|
|
A |
0.730 |
GeneticVariation |
GWASCAT |
Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.
|
26908601 |
2016 |
|
rs1799963
|
|
A |
0.730 |
GeneticVariation |
GWASCAT |
Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.
|
25772935 |
2015 |
|
rs1799963
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Factor V Leiden (FVL or rs6025) and prothrombin gene G20210A (PT or rs1799963) are the genetic variants currently tested for VTE risk assessment.
|
25341889 |
2014 |
|
rs1799963
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Apart from F5 rs6025, ABO rs8176719, rs2519093 and F2 rs1799963, additional common and high VTE-risk SNPs among whites are unlikely.
|
22672568 |
2012 |
|
rs3136516
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.
|
31420334 |
2019 |
|
rs3136516
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.
|
28373160 |
2017 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed at establishing a real-time PCR protocol for the detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and prothrombin (F2) c.20210G>A from whole blood, without DNA extraction.
|
30439355 |
2019 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, coagulant factor V gene G1691A mutation and protein S deficiency constitute important genetic risk factors in patients with VTE in Eastern Algeria.
|
26304686 |
2017 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V Leiden, PTH G20210A and MTHFR C677T polymorphisms were detected in 40 cancer patients with VTE (group 1) and 40 cancer patients with no evidence of VTE (group 2) by PCR-based DNA analysis.
|
25565385 |
2015 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MTHFR C677T had no association with VTE risk in pregnancy (ORG 1.24; 95% CI 0.88-1.73).
|
26115054 |
2015 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No significant association with VTE was found for homozygous C677T MTHFR (OR: 1.38; 95 % confidence intervals [CI]: 0.98-1.93), whereas the risk was increased in carriers of either heterozygous FVL or PT20210 (OR = 4.22; 95 % CI: 3.35-5.32; and OR = 2.79;95 % CI: 2.25-3.46, respectively), in double heterozygotes (OR = 3.42; 95 %CI 1.64-7.13), and in homozygous FVL or PT20210A (OR = 11.45; 95 %CI: 6.79-19.29; and OR: 6.74 (CI 95 % 2.19-20.72), respectively).
|
23900608 |
2013 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism.
|
22528331 |
2012 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, frequencies of FV G1691A, PT G20210A, and MTHFR C677T mutations are higher in patients with VTE.
|
21078611 |
2012 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism.
|
22528331 |
2012 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Coagulation factor II G20210A and coagulation factor V (Leiden) G1691A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism.
|
22744422 |
2012 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE).
|
19520679 |
2010 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients were interviewed about VTE risk factors and tested for factor V Leiden (FVL), prothrombin G20210A (PT), methylenetetrahydrofolate reductase C677T homozygosity (MTHFR), lupus anticoagulant, homocysteine (Hcy) and plasma factor VIII (FVIII) levels.
|
19853891 |
2010 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE).
|
19520679 |
2010 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present study, we have focused on the prevalence of methylenetetrahydrofolate reductase (MTHFR) C677T, dihydrofolate reductase (DHFR) 19-bp deletion within intron 1, factor V Leiden (FVL), and prothrombin (PT) G20210A polymorphisms in cancer patients with and without VTE.
|
18682947 |
2009 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MTHFR/ C677T in Chinese/Thai populations (OR 1.57; 95% CI 1.23-2.00, p = 0.0003), and ACE I/D in African American populations (OR 1.5; 95% CI 1.03-2.18, p = 0.03) were found to be significantly associated with VTE.
|
19652888 |
2009 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Statistically significant associations with VTE were identified for factor V G1691A (OR 9.45; 95% CI 6.72-13.30, p < 0.0001), factor V A4070G (OR 1.24; 95% CI 1.02-1.52, p = 0.03), prothrombin G20210A, (OR 3.17; 95% CI 2.19-3.46, p < 0.00001), prothrombin G11991A, (OR 1.17; 95% CI 1.07-1.27, p = 0.0007), PAI-1 4G/5G, (OR 1.62; 95% CI 1.22-2.16, p = 0.0008), alpha-fibrinogen Thr312Ala (OR 1.37; 95% CI 1.14-1.64, p = 0.0008), all in Caucasian populations.
|
19652888 |
2009 |